Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Methamphetamine Use Disorder
NCT05322954Phase 1Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in methamphetamine use disorder (MUD), sponsored by University of Wisconsin–Madison. Primary endpoint: Incidence of serious adverse events associated with oral psilocybin at 26 weeks. Started Mar 2023; status: terminated.
02
Drugs
psilocybin
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT05322954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322954.